Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of nerandomilast in pulmonary fibrosis after prior BI 1015550 trials
NL-OMON60301Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nerandomilast in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of any adverse event. Started Sep 2024; status: active, not recruiting.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NL-OMON60301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60301.